DK1948217T3 - Anvendelse af nervevækstfaktor i øjendråber til terapi af patologier af centralnervesystemet såsom Alzheimers og Parkinsons sygdom - Google Patents

Anvendelse af nervevækstfaktor i øjendråber til terapi af patologier af centralnervesystemet såsom Alzheimers og Parkinsons sygdom

Info

Publication number
DK1948217T3
DK1948217T3 DK06780613.3T DK06780613T DK1948217T3 DK 1948217 T3 DK1948217 T3 DK 1948217T3 DK 06780613 T DK06780613 T DK 06780613T DK 1948217 T3 DK1948217 T3 DK 1948217T3
Authority
DK
Denmark
Prior art keywords
disease
parkinson
alzheimer
therapy
growth factor
Prior art date
Application number
DK06780613.3T
Other languages
English (en)
Inventor
Alessandro Lambiase
Stefano Bonini
Original Assignee
Anabasis S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anabasis S R L filed Critical Anabasis S R L
Application granted granted Critical
Publication of DK1948217T3 publication Critical patent/DK1948217T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK06780613.3T 2005-08-19 2006-08-11 Anvendelse af nervevækstfaktor i øjendråber til terapi af patologier af centralnervesystemet såsom Alzheimers og Parkinsons sygdom DK1948217T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000447A ITRM20050447A1 (it) 2005-08-19 2005-08-19 Uso del nerve growth factor in collirio nella terapia di patologie del sistema nervoso centrale, quali la malattia di alzheimer e il morbo di parkinson.
PCT/IT2006/000620 WO2007020672A2 (en) 2005-08-19 2006-08-11 Use of nerve growth factor in eye-drops for therapy of pathologies of the central nervous system, such as alzheimer's and parkinson's disease

Publications (1)

Publication Number Publication Date
DK1948217T3 true DK1948217T3 (da) 2012-02-20

Family

ID=37667295

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06780613.3T DK1948217T3 (da) 2005-08-19 2006-08-11 Anvendelse af nervevækstfaktor i øjendråber til terapi af patologier af centralnervesystemet såsom Alzheimers og Parkinsons sygdom

Country Status (11)

Country Link
US (1) US20090118177A1 (da)
EP (1) EP1948217B1 (da)
JP (1) JP2009504724A (da)
AT (1) ATE539763T1 (da)
CA (1) CA2619721A1 (da)
DK (1) DK1948217T3 (da)
ES (1) ES2376992T3 (da)
IL (1) IL189605A (da)
IT (1) ITRM20050447A1 (da)
RU (1) RU2429007C2 (da)
WO (1) WO2007020672A2 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008271911B2 (en) * 2007-06-29 2014-08-07 Phovitreal Pty Ltd Treatment or prophylaxis or neurological or neuropsychiatric disorders via ocular administration
CN101972224B (zh) * 2010-09-13 2012-01-04 舒泰神（北京）生物制药股份有限公司 一种眼用原位凝胶
IT202000032423A1 (it) 2020-12-24 2022-06-24 Univ Degli Studi Di Trieste Metodo per la produzione di forme processate proteoliticamente di fattori trofici o fattori di crescita

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959319A (en) * 1985-08-01 1990-09-25 Skelnik Debra L Process of corneal enhancement
US4973466A (en) * 1988-06-21 1990-11-27 Chiron Ophthalmics, Inc. Wound-healing dressings and methods
US5767079A (en) * 1992-07-08 1998-06-16 Celtrix Pharmaceuticals, Inc. Method of treating ophthalmic disorders using TGF -β
US5641749A (en) * 1995-11-29 1997-06-24 Amgen Inc. Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
US5641750A (en) * 1995-11-29 1997-06-24 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
US6063757A (en) * 1995-11-29 2000-05-16 Urso; Richard G. Wound treatment method with nerve growth factor
IT1283911B1 (it) * 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US6299895B1 (en) * 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
CN1233963A (zh) * 1996-09-13 1999-11-03 有限会社最先端医学研究所 神经营养因子的眼科用组合物、视神经机能障碍治疗药和视神经机能障碍治疗方法
IT1291892B1 (it) * 1997-04-24 1999-01-21 Alessandro Lambiase Uso del nerve growth factor nella conservazione di cornee in coltura, nella produzione di tessuti corneali e congiuntivali in vitro e nella
WO2000007613A1 (fr) * 1998-08-05 2000-02-17 Advanced Medicine Research Institute Remedes contenant des facteurs neurotrophiques pour le traitement des lesions cerebrales centrales
JP2002531490A (ja) * 1998-12-09 2002-09-24 カイロン コーポレイション 中枢神経系に薬剤を投与するための方法
IT1305294B1 (it) * 1999-01-29 2001-05-04 Alessandro Lambiase Uso del nerve growth factor nella terapia di patologie a carico deitessuti intraoculari.
US20020009498A1 (en) * 1999-11-05 2002-01-24 Guy L. Clifton Methods and compositions for treatment of traumatic brain injury
IL147921A0 (en) * 2002-01-31 2002-08-14 Abdulrazik Mohammad A method for treating central nervous system disorders by ocular dosing

Also Published As

Publication number Publication date
RU2008110505A (ru) 2009-09-27
ES2376992T3 (es) 2012-03-21
US20090118177A1 (en) 2009-05-07
ATE539763T1 (de) 2012-01-15
JP2009504724A (ja) 2009-02-05
WO2007020672A3 (en) 2007-05-31
WO2007020672A2 (en) 2007-02-22
ITRM20050447A1 (it) 2007-02-20
EP1948217A2 (en) 2008-07-30
IL189605A0 (en) 2008-06-05
CA2619721A1 (en) 2007-02-22
EP1948217B1 (en) 2012-01-04
IL189605A (en) 2013-10-31
RU2429007C2 (ru) 2011-09-20

Similar Documents

Publication Publication Date Title
Cai Monoamine oxidase inhibitors: promising therapeutic agents for Alzheimer's disease
Dietz et al. HDAC inhibitors and neurodegeneration: at the edge between protection and damage
Stein et al. Beta oscillations in the cortico-basal ganglia loop during parkinsonism
MX2011002705A (es) Compuestos con anillos espiro-triciclicos como moduladores de beta-secretasas y metodos de uso.
WO2012006419A3 (en) Pro-neurogenic compounds
MX2012005131A (es) Enfoques terapeuticos nuevos para tratar la enfermedad de alzheimer.
WO2009132656A3 (en) Crystal structure of human sortilin and uses thereof for identifying ligands to sortilin
NO20081367L (no) Fenyl- og pyridyl-1,2,4-oksadiazolonderivater med fenylgruppe, fremgangsmater for fremstilling derav og deres anvendelse som farmasoytika
Wang et al. Therapeutic strategies for Parkinson’s disease: the ancient meets the future—traditional Chinese herbal medicine, electroacupuncture, gene therapy and stem cells
Ruff et al. The potential for stem cell therapies to have an impact on cerebral palsy: opportunities and limitations
NO20060080L (no) Pyrrol-2,5-ditionderivater som Lever X reseptormodulatorer
MX2012010657A (es) Compuestos de espiro amino-dihidrooxazina y amino-dihidrotiazina como moduladores de beta-secretasa y su uso medico.
BR112015004942A2 (pt) benzimidazóis como agentes ativos do snc
MX2022009528A (es) Derivados de 3-pirrolidina-indol como agentes psicodélicos serotoninérgicos para el tratamiento de trastornos del snc.
Wei et al. Geniposide attenuates epilepsy symptoms in a mouse model through the PI3K/Akt/GSK‑3β signaling pathway
DK1948217T3 (da) Anvendelse af nervevækstfaktor i øjendråber til terapi af patologier af centralnervesystemet såsom Alzheimers og Parkinsons sygdom
WO2012005509A3 (ko) 코받침 높낮이 조절식 안경프레임
Nakamagoe et al. Downbeat nystagmus due to a paramedian medullary lesion
Alosaimi et al. The role of neurotransmitter systems in mediating deep brain stimulation effects in Parkinson’s disease
KR101273296B1 (ko) 시신경 자극용 안경
NO20081675L (no) Cykliske N-[1,3,4]-tiadiazol-2-yl-benzensulfonamlder, fremgangsmate for fremstilling derav og deres anvendelse som farmasoytika
Calne Parkinsonism: Clinical and neuropharmacologic aspects
Leston Functional anatomy of the trigeminal nerve
BR112015008200A2 (pt) derivados de imidazopiridina
Jiao Embryonic and adult neural stem cell research in China